PCI Pharma expands global sterile fill-finish capacity
The company acquires three automated sterile fill-finish machines for its facilities in San Diego and Melbourne, which are now fully operational.
The company acquires three automated sterile fill-finish machines for its facilities in San Diego and Melbourne, which are now fully operational.
More than a year after imposing a clinical hold on MaaT Pharma’s lead microbiome therapeutic in 2021, the US Food and Drug Administration (FDA) has given clearance for the French firm to begin a phase 3 trial in the US.
The two companies will enter a strategic license agreement to develop ADCs, which gives BMS rights to Tubulis’ technology.
The new €350m ($386m) biotechnology research center will help power Boehringer Ingelheim’s development of biopharmaceuticals, which account for around 50% of the company’s research pipeline.